



Medi-Cal Rx Monthly Bulletin

January 1, 2026

Medi-Cal Rx has implemented or scheduled the following updates. Stay up to date with all that is happening at Medi-Cal Rx by visiting the [Bulletins & News](#) page and signing up for the [Medi-Cal Rx Subscription Service](#) to receive notification of future publications.

1. [Updates to the Medi-Cal Rx Contract Drugs List](#)
2. [Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes](#)
3. [Updates to the Medi-Cal Rx Provider Manual](#)
4. [Update: Long Term Care Claims Processing](#)
5. [New Compounding Pharmacy Attestation Form Available](#)
6. [Updates to the Pharmacy Provider Dispensing Fee Self-Attestation – Frequently Asked Questions \(FAQs\)](#)
7. [Updates to the GLP-1 Drugs – Medi-Cal Rx Members' Frequently Asked Questions \(FAQs\)](#)

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the [Medi-Cal Rx Contract Drugs List](#) (CDL) and to the [Medi-Cal Rx Diagnosis Crosswalk](#) *.

Drug Name	Description
Blinatumomab	Prior authorization (PA) required.
Dulaglutide *	Diagnosis restriction added.
Gemcitabine HCL	Additional formulation (multi-dose vials) added to the CDL with labeler restriction (LR).
Liraglutide (Saxenda)	Removed from the CDL.
Semaglutide (Wegovy)	Removed from the CDL.
Tirzepatide (Zepbound)	Removed from the CDL.
Tralokinumab-Idrm *	Added to the CDL with age limit (AL), LR, quantity limit (QL), and diagnosis restrictions.

2. Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes

The following updates have been made to the [Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes](#).

Labeler Code Additions

NDC Labeler Code	Contracting Company's Name
82568	AARNA USA INC.
68002	AMERICAN HEALTH PACKAGING
83390	COSETTE PHARMACEUTICALS NC LABORATORIES, LLC
84015	CRINETICS PHARMACEUTICALS, INC.
85592	CUMBERLAND ASSURED PRODUCTS INC.
69945	CURIUM US LLC
75833	DELCATH SYSTEMS, INC.
68118	ESTEVE PHARMACEUTICALS, LLC
63561	GRANULATION TECHNOLOGY, INC.
87127	HAPPY ROBIN, LLC
68547	LA JOLLA PHARMACEUTICAL COMPANY

NDC Labeler Code	Contracting Company's Name
54828	LIFE MOLECULAR IMAGING, LTD
84768	PRECIGEN, INC.
71741	REDMONT PHARMACEUTICALS LLC
83245	SCIENTURE, LLC
72359	SUMITOMO PHARMA AMERICA, INC.
72374	TANVEX BIOPHARMA USA, INC.

Labeler Code Terminations

NDC Labeler Code	Contracting Company's Name
70504	APTEVO BIOTHERAPEUTICS LLC
80735	CIPLA THERAPEUTICS INC.
71565	CLEARSIDE BIOMEDICAL INC.
82429	GABAR HEALTH SCIENCES
71247	INNOGENIX, LLC
83592	TRUE MARKER PHARMACEUTICALS, INC.
76439	VIRTUS PHARMACEUTICALS, LLC

3. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the [Medi-Cal Rx Provider Manual](#).

Section	Update Description
<i>Section 4.6.11 – Items Not Covered</i>	<ul style="list-style-type: none"> Added additional pharmacy items that are excluded from reimbursement under Medi-Cal Rx including glucagon-like peptide-1 (GLP-1) drugs with exceptions, non-legend cough and cold products, and extended-release over-the-counter (OTC) cough/cold preparations.
<i>Section 4.6.12 – Continuing Care</i>	<ul style="list-style-type: none"> Refined language regarding continuing care being removed from the <i>Welfare and Institutions Code</i> (W&I Code) and medical necessity exceptions. Removed language regarding PA requirements and exemptions for continuing care.

Section	Update Description
<i>Section 11.2.1 – List of Drugs Subject to Restriction</i>	<ul style="list-style-type: none"> Refined language to clarify Medi-Cal Rx pharmacy benefit coverage. Removed the anorexia U.S. Food and Drug Administration (FDA) indication from the list of drugs subject to restriction.
<i>Section 14.7 – PA Adjudication</i>	<ul style="list-style-type: none"> Refined language regarding information submitted with a PA request supporting medical necessity.
<i>Section 14.8 – Establishing Medical Necessity for PA Requests</i>	<ul style="list-style-type: none"> Added language regarding the requirement to rule out least costly drug/products before requesting a PA and enforcement of trial or patient-specific consideration of less costly alternatives. Added language explaining that continuation of therapy alone will not suffice as justification for establishing medical necessity.
<i>Section 15.12 – Pharmacist Services</i>	<ul style="list-style-type: none"> Added furnishing HIV pre-exposure and post-exposure prophylaxis as an included pharmacist service.
<i>Section 19.1.1 – Completion Instructions for the UCF</i>	<ul style="list-style-type: none"> Updated route of administration (ROA) and Systematized Nomenclature of Medicine (SNOMED) value information for Field 66.
<i>Section 19.2.2.1 – Completion Instructions for California Specific Compound Pharmacy Claim Form (30-4)</i>	<ul style="list-style-type: none"> Updated ROA and SNOMED value information for Field 48.
<i>Appendix C – Aid Codes</i>	<ul style="list-style-type: none"> Updated the Recipient Aid Code Level Benefits description for multiple aid codes.

4. Update: Long Term Care Claims Processing

Effective January 1, 2026, Medi-Cal Rx will implement the following updates to claims processing for Medi-Cal members residing in Long Term Care (LTC) facilities:

- Claims submitted for products not reimbursable by Medi-Cal Rx will deny with **Reject Code 70 – Product/Service Not Covered** with the supplemental message *“Requested product is included in facility per diem rate and not separately payable.”*
- Claims submitted for enteral nutritional products will not be covered.

Notes:

- Claims submitted for members residing in LTC facilities must be submitted with a Patient Residence code value of 3 – Nursing Facility or 9 – Intermediate Care Facility/Individuals with Intellectual Disabilities in NCPDP Field 384-4X.

- Claims for products not reimbursable by Medi-Cal Rx should be billed as part of the facility's per diem rate.
- LTC claims processing for other situations will continue as outlined in the *Long Term Care Claims Processing* section in the [*Medi-Cal Rx Provider Manual*](#).
- As a reminder, claims are monitored for program integrity by the Department of Health Care Services' (DHCS) Audits & Investigations (A&I) Division. Refer to the *Medi-Cal Rx Program Integrity* section in the *Medi-Cal Rx Provider Manual* for more information.

5. New Compounding Pharmacy Attestation Form Available

Medi-Cal Rx published the new [*Compounding Pharmacy Attestation \(DHCS 7411\)*](#) form on November 24, 2025. To access the document, visit the [*Medi-Cal Rx Provider Portal*](#) and select the **Reference Materials** tab on the [*Forms & Information*](#) page.

Pharmacy providers must complete all required fields to be added to the Medi-Cal Rx Compounding Pharmacies List.

6. Updates to the Pharmacy Provider Dispensing Fee Self-Attestation – Frequently Asked Questions (FAQs)

Medi-Cal Rx published updates to the [*Pharmacy Provider Dispensing Fee Self-Attestation – Frequently Asked Questions \(FAQs\)*](#) on January 1, 2026. To access the document, visit the [*FAQ*](#) page on the [*Medi-Cal Rx Web Portal*](#).

7. Updates to the GLP-1 Drugs – Medi-Cal Rx Members' Frequently Asked Questions (FAQs)

Medi-Cal Rx published updates to the [*GLP-1 Drugs – Medi-Cal Rx Members' Frequently Asked Questions \(FAQs\)*](#) on December 17, 2025, and on December 29, 2025. To access the document, visit the [*FAQ*](#) page on the [*Medi-Cal Rx Web Portal*](#) or select the **State Budget Policy Updates** tab on the [*Education & Outreach*](#) page.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.